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Cognitive impairments are highly prevalent in Parkinson’s disease (PD) and can substantially affect a patient’s quality
of life. These impairments remain difficult to manage with current clinical therapies, but exercise has been identified
as a possible treatment. The objective of this systematic review was to accumulate and analyze evidence for the
effects of exercise on cognition in both animal models of PD and human disease. This systematic review was
conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement.
Fourteen original reports were identified, including six pre-clinical animal studies and eight human clinical studies.
These studies used various exercise interventions and evaluated many different outcome measures; therefore, only a
qualitative synthesis was performed. The evidence from animal studies supports the role of exercise to improve
cognition in humans through the promotion of neuronal proliferation, neuroprotection and neurogenesis. These
findings warrant more research to determine what roles these neural mechanisms play in clinical populations.
The reports on cognitive changes in clinical studies demonstrate that a range of exercise programs can improve
cognition in humans. While each clinical study demonstrated improvements in a marker of cognition, there
were limitations in each study, including non-randomized designs and risk of bias. The Grading of Recommendations
Assessment, Development and Evaluation (GRADE) system was used and the quality of the evidence for human studies
were rated from “low” to “moderate” and the strength of the recommendations were rated from “weak” to “strong”.
Studies that assessed executive function, compared to general cognitive abilities, received a higher GRADE rating.
Overall, this systematic review found that in animal models exercise results in behavioral and corresponding
neurobiological changes in the basal ganglia related to cognition. The clinical studies showed that various types
of exercise, including aerobic, resistance and dance can improve cognitive function, although the optimal type,
amount, mechanisms, and duration of exercise are unclear. With growing support for exercise to improve not
only motor symptoms, but also cognitive impairments in PD, health care providers and policy makers should
recommend exercise as part of routine management and neurorehabilitation for this disorder.
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Rationale and objective
Aside from well-documented motor symptoms, most
Parkinson’s disease (PD) patients suffer from associated
non-motor complications, including cognitive impair-
ment, mood disorders, olfactory dysfunction, sleep dis-
turbance, fatigue and anxiety [1-3]. Of the non-motor
symptoms, cognitive impairments are particularly preva-
lent in PD with up to 83% of patients developing* Correspondence: danielle.k.murray@gmail.com
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unless otherwise stated.dementia after 20 years [4]. The non-motor symptoms
of PD can be at least as detrimental as motor manifesta-
tions for a patient’s health and overall quality of life, but
unfortunately remain difficult to manage with current
clinical therapies [1-3].
The current gold-standard for testing global cognitive
capacity in clinical practice includes objective verbal and
written tests. Of the quick screening cognitive tests
available, the Montreal Cognitive Assessment (MoCA)
[5] has been widely accepted for use in PD populations
[6] by assessing multiple domains of cognitive function
including memory, language, complex visuospatial pro-
cessing, and executive function. This validated tool hasLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cognition. Animal models of PD provide a more readily
controlled means to assess cellular dysfunction, neuro-
chemical alterations and other neural mechanisms that
may contribute to disease pathogenesis in humans.
Exercise is thought to improve overall wellbeing in
older adults and benefit cognitive functions of those with
neurodegenerative diseases [7]. It has been suggested
that exercise may improve the motor manifestations of
PD and that restricted use in rats may potentiate neuro-
degeneration [8]. Specifically, evidence has shown that
exercise is beneficial for bradykinesia, postural balance
and quality of life in patients with PD [9-12]. The extent
to which exercise specifically impacts cognition in PD,
and how, is unclear. A non-systematic review from 2011
suggested that vigorous exercise may have a neuroprotec-
tive effect in PD [13]. A more recent systematic review
similarly showed that non-pharmacological interventions
improve cognition in PD. However, this review included
only those studies published before December 2011 and
used limited search terms related to cognition, resulting in
the review of only four clinical studies [14]. A subsequent
analysis of the literature was needed to include recent
clinical studies and to incorporate animal-based research
that might help identify potential mechanisms in humans.
Therefore, this systematic review was conducted to evalu-
ate all original research reports that assessed exercise in-
terventions in human PD or in animal models of PD, with
a primary or secondary outcome to examine cognitive
function. To provide the most comprehensive overview of
the literature, non-randomized, pre-post and cohort trials
were included in addition to randomized controlled trials.
The combination of these findings should be used to fur-
ther guide clinical practice and neurorehabilitation exer-
cise programs toward treating cognitive deficits in PD.
Methods
Systematic review protocol
This systematic review was conducted according to the Pre-
ferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) statement guidelines [15]. The PRISMA
statement includes a 27-item checklist (Additional file 1)
and standardized instructions for conducting a systematic
review. The complete search methodology, information
sources and results for this review are described within this
report and Appendix 1.
Eligibility criteria for study characteristics
The participants included healthy human subjects, sub-
jects with PD and animals with experimental PD. Studies
were included if their primary intervention was exercise
and their primary or secondary outcomes were to assess
either behavioral or neurobiological markers of cognitive
function. All articles were included where the authorstreated the outcome measure as a test of cognition. In
some cases, the measure was a surrogate (e.g., biomarker
associated with cognitive function), was a sub-score of
cognition from a larger scale, or was influenced by
motor capacity. An exercise intervention was defined as
any purposeful increase in the subject’s physical activity
through a single bout of exercise or prolonged exercise
over the course of a structured or unstructured program.
Cohort and experimental study designs were included,
whereas case series, case–control, cross-sectional and
descriptive studies were excluded. Original research arti-
cles were included from 1966 through October 2013.
Studies were considered if they were written in the
English language and either published or “in press”.
Results
Study selection and synthesis
There were 14 records included in this analysis (Figure 1).
Thirteen records were found through searching databases
and one record [16] was found through searching the ref-
erences of articles identified for inclusion in the analysis.
The records comprised six pre-clinical animal studies (all
on rodents) and eight clinical studies in humans. Of the
six pre-clinical studies, all were randomized controlled
studies. Two studies examined the effects of exercise on
unspecified aspects of cognition [17,18], and four studies
examined the effects of exercise specifically on learning
and memory [16,19-21]. Of the eight clinical studies, four
studies examined the effects of exercise on unspecified as-
pects of cognition [22-25], and four studies examined the
effects of exercise specifically on tasks of executive func-
tion [26-29]. The clinical studies included five randomized
controlled trials, one controlled trial and two pre-post tri-
als. A quantitative comparison or meta-analysis could not
be performed for either the pre-clinical or clinical studies
because there were only a small number of reports identi-
fied, and when compiled together they had heterogeneous
patient populations, exercise interventions and outcome
measures.
Study characteristics and results for pre-clinical studies
All six pre-clinical studies were randomized controlled trials.
Three different toxins were used to generate basal ganglia le-
sions and develop models of PD in rodents. Three studies
used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
in mice [16,17,20], two studies used 6-hydroxydopamine
(6-OHDA) in rats [18,30], and one study used reser-
pine in rats [19], resulting in reversible monoamine de-
pletion. The timing of toxin administration varied
relative to the onset of the exercise program. Four
studies tested the effect of exercise that started follow-
ing the lesion [16-18,30]. The interventions were five
days per week for 30 days starting within a week after
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Figure 1 PRISMA Flow Diagram of Study Selection.
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weeks during, and for 8–12 weeks following chronic
MPTP administration [20]. The study that used reserpine
tested exercise five days per week for 30 days prior to ad-
ministration of the toxin in order to assess how exercise
may prevent cognitive impairment in PD [19].
Four studies looked at forced exercise on a treadmill
compared to no exercise [16,18,20,30]. Three studies
showed potential neurobiological correlates of observed
behavioral changes that the authors related to cognition,
including findings from one study that rats forced to ex-
ercise had better behavioral recovery on tests of motor
function (i.e., cylinder and amphetamine-induced rota-
tional tests), and better preservation of tyrosine hydroxy-
lase immunoreactivity in both striatum and substantia
nigra [18]. The authors also found that exercise in-
creased the migration of BrdU and doublecortin-positive
cells as well as increased brain-derived neurotrophic fac-
tor (BDNF) and glial cell line-derived neurotrophic fac-
tor (GDNF) in the striatum on the side of the lesion. In
another study, exercise resulted in enhanced duration
and velocity of running behavior, indicating that rats had
learned to maintain a forward position on a treadmill[16]. Exercise in these MPTP- and saline-injected mice
resulted in significant down-regulation of striatal dopa-
mine transporter protein (DAT) as well as increased D2
(but not D1) receptor mRNA expression. Exercise atten-
uated the increase in striatal glutamate nerve terminal
labeling following MPTP, but there was no change in
glutamate immunolabeling in CA1 in the hippocampus.
In both of these studies exercise improved behavioral
markers that were interpreted by the authors as indica-
tive of enhanced cognitive function. It should be noted
that these measures rely heavily on motor capacity and
are typically associated more with motor than with cog-
nitive function. The third study that showed neurobio-
logical changes associated with corresponding behavioral
changes tested effects of aerobic swimming in mice. The
rodents showed improved long-term memory on a test
of object recognition following exercise and had at-
tenuation of impairments from exposure to 6-OHDA,
including decreased pro-inflammatory cytokines, im-
proved markers of oxidative stress and increased DA
transmission [30]. The last study that looked at forced
exercise on a treadmill compared to no exercise con-
ducted in a chronic model of PD found that endurance
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ambulation and balance, with no improvement in cog-
nitive measures [20]. This study was also the only one
of these four where exercise did not improve a neuro-
biological outcome following toxin administration, in-
cluding no raise in striatal DA and no reversed loss of
tyrosine-hydroxylase fibers in the substantia nigra pars
compacta.
Two studies (one with MPTP and one with reserpine)
looked at the effects of voluntary exercise (wheel run-
ning), compared to forced exercise on a treadmill or no
exercise [17,19]. In one study, exercise was introduced
prior to the administration of reserpine [19], while in the
other [17], exercise was not initiated until after the
MPTP lesion. Both studies found that either form of ex-
ercise improved behavior underlying cognitive capacity
in a PD-like model. Interestingly, only forced exercise,
following the lesion, improved a test of motor learning
(transfer of treadmill performance to Rotarod). The au-
thors suggested this finding reflects learning as the ani-
mals had presumably transferred skill from the treadmill
to the Rotarod task [17]. The rodents forced to exercise
on the treadmill showed a greater improvement on the
Rotarod test, even though rodents on the wheel willingly
spent more time exercising than those forced to run on
the treadmill. Both voluntary and forced exercise had
anxiolytic effects as assessed using the elevated plus
maze, which the authors linked to cognition and mem-
ory, but neither type of exercise had any effect on de-
pressive behavior as assessed by sucrose preference and
tail suspension. These improvements were not associ-
ated with changes in the striatal DA or amygdalar sero-
tonin (5HT) levels following the exercise intervention, as
compared to saline-treated sedentary controls [17].
However, both MPTP- and saline-treated mice had a
similar relative increase in striatal DA following forced
or voluntary exercise compared to saline-treated seden-
tary controls. Forced exercise also increased 5HT in the
nucleus accumbens in the MPTP-treated mice compared
to saline controls. In the second study, when either
forced or voluntary exercise was introduced prior to re-
serpine administration, both exercise paradigms resulted
in improved motor learning on the Rotarod and open-
field tasks (tests of exploratory activity), as well as im-
proved social memory [19]. Social memory improved
with a low dose or reserpine which, unlike the high dose
of the toxin, did not affect the animals’ motor function.
Biomarkers were not assessed in this study.
Further details of study characteristics and results for
pre-clinical studies are summarized in Tables 1 and 2.
Major sources of risk of bias for pre-clinical studies
One of the six pre-clinical animal studies was at risk of
selection bias because the investigators did not include asaline-only control group or an exercise and probenecid
group, although it was still a randomized controlled trial
[20]. Three other pre-clinical studies were at risk of in-
formation biases; in one case the cognitive assessment
relied on motor capacity [16], in another case the behav-
ioral testing began soon after administration of the
toxin, which may have interrupted the lesion process
(not measured) and made the model less comparable to
PD in human subjects [19] and in the third case the ex-
ercise was started soon after the toxin was administered,
which may also have interrupted the lesion process [16].
Two studies had performance biases, specifically that
each animal was only evaluated on one test [17] and that
exercised mice were trained for swimming for two weeks
before toxin administration and handled each session,
whereas the sedentary animals were not trained or han-
dled [30]. Additionally, the social interaction (i.e., hous-
ing environment) the animals experienced was different
in each of the six studies, making it difficult to compare
results across studies. The number of rodents housed in
a cage ranged from one to ten, and one study did not
specify the housing environment. Paired housing com-
pared to single housing in rodents has been shown to
mediate the effects of MPTP on nigrostriatal degener-
ation and motor behavior [31] and may have a substan-
tial effect on behavioral and histological outcomes. The
risk of bias for each pre-clinical study is summarized in
Table 2.
Study characteristics and results for clinical studies
All eight studies showed that exercise improved a
marker of cognition (Table 3). Based on the GRADE
ranking system, the quality of the evidence and strength of
recommendations for the four studies on executive func-
tion were greater (“moderate” and “strong”) than for stud-
ies testing unspecified aspects of cognitive function (“low”
and “weak”).
The sample size for the eight clinical studies varied
from six to 60 subjects, with a mean of 15 subjects per
group. The PD participants had a mean age between 60
to 70 years and had mild to moderate PD according to
the Hoehn and Yahr scale [34], and were compared to
age-matched healthy control subjects. All of these stud-
ies examined subjects while they were taking their regu-
larly prescribed medication. These studies did not report
when subjects took their regular medication and which
medications they continued to take during the study.
Each of the four studies that tested the effect of exer-
cise on unspecified aspects of cognition found benefits
on general markers of overall function which the authors
related to cognition, including the cognition component
of PDQ-39, MoCA, memory, reaction time and peg in-
sertion time (requiring visual and spatial cognition, sort-
ing and planning) [22-25]. The evidence from two of the
Table 1 Study characteristics of pre-clinical studies on rodent models of Parkinson’s disease
Authors Study title Subjects Intervention
Goes et al., 2013 [21] Neuroprotective effects of swimming
training in a mouse model of Parkinson’s
disease induced by 6-hydroxydopamine
• 2 groups (n = 20 each): 6-OHDA, saline • 20–60 min/day, 5 days/week
for 4 weeks
• 2 treatment cohorts (n = 10 each):
swimming training, no exercise • Starting 4 days after toxin
administration
Gorton et al., 2010 [17] Exercise effects on motor and
affective behavior and catecholamine
neurochemistry in the MPTP-lesioned
mouse
• 2 groups (n = 24 each): MPTP, saline • Up to 1 hr/day, 5 days/week
for 4 weeks
• 3 treatment cohorts (n = 8/group):
forced exercise, voluntary exercise,
no exercise
• Starting 5 days after toxin
administration
Tajiri et al., 2010 [18] Exercise exerts neuroprotective effects
on Parkinson's disease model of rats
• 1 group (n = 60): 6-OHDA • 30 min/day, 5 days/week for
4 weeks
• 2 treatment cohorts (n = 30 each):
forced exercise, no exercise • Starting 1 day after toxin
administration
Aguiar et al., 2009 [19] Physical exercise improves motor and
short-term social memory deficits in
reserpinized rats
• 4 groups (n = 24 each): high/low
dose reserpine or high/low dose
saline
• 20–25 min/day, 5 days/week
for 4 weeks
• Starting 4 weeks before toxin
administration• 3 treatment cohorts± (n = 8/group):
forced exercise, voluntary exercise,
no exercise
Pothakos et al., 2009
[20]
Restorative effect of endurance exercise
on behavioral deficits in the chronic
mouse model of Parkinson's disease
with severe neurodegeneration
• 2 groups (n = 29 each): probenecid/MPTP
(model of chronic PD), probenecid only
• 40 min/day, 5 days/week for
8–12 weeks
• Starting 1 week before, 5 weeks
during, 8–12 weeks after toxin
administration
• 2 treatment cohorts (n = 5-10/group):
forced endurance exercise, no
exercise – for probenicid/MPTP group
only
Fisher et al., 2004 [16] Exercise-induced behavioral recovery and
neuroplasticity in the 1-methyl-4-phenyl-1,
2,3,6-tetrahydropyridine- lesioned mouse
basal ganglia
• 2 groups (n = 60 each): MPTP, saline • Up to 2x 30 min/day, 5 days/week
for 4 weeks
• 2 treatment cohorts (n = 20/group):
forced exercise, no exercise* • Starting 4 days after toxin
administration
±Only rats able to maintain a forward position on the treadmill were assigned to the treadmill exercise group.
*Only rats able to maintain a forward position on the treadmill were randomized to either exercise or no exercise cohort.
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feasibility [22,23]. Additionally, the measures of cogni-
tion these studies used, the cognition component of
PDQ-39, reaction time and peg insertion, are not clear
measures of cognitive function. However, the two other
studies clearly demonstrated that exercise had an effect
on cognitive capacity [24,25]. Of these two trials, both
tested the Wii FitTM program. They showed that after
training, PD subjects can retain and transfer learning, de-
pending on the cognitive demands of the game, [25] but
Wii FitTM may not provide additional advantage in com-
parison to balance exercises without cognitive stimulation
or feedback [24].
Across studies, exercise interventions varied signifi-
cantly in terms of the intensity, mode and duration of
the program. One study involved an individualized walk-
ing program (PoleStriding) using Nordic poles three
times per week for eight weeks [22]. Another study
assessed outcomes before and after a single bout of
high-intensity cycling [23]. The two studies that used the
Wii FitTM program for their exercise intervention in-
cluded two sessions per week for seven weeks andfollow-up after 60 days [24,25]. One of the two studies
using Wii FitTM compared PD subjects to healthy con-
trols [25] and the other study looked at differences be-
tween PD subjects participating in the combined Wii
FitTM program with balance-based and cognitive training
compared to multimodal global exercises [24].
Each of the four studies that specifically tested execu-
tive function showed that exercise improved perform-
ance on some measure of executive function, such as
tests of abstraction, mental flexibility, spatial working
memory, verbal fluency, mental imagery, and cognitive
processing speed [26-29]. The tools used to test execu-
tive function include the Wisconsin Card Sorting Task,
Trail-Making Test A and B, Cambridge Neuropsycho-
logical Test Automated Battery, and tests of verbal and
semantic fluency. Two studies assessed mood as a po-
tential confounding factor affecting executive function;
one study found that exercise improved executive func-
tion independent of improvements in mood, attention,
disease-specific quality of life or reduced anxiety [27].
Another study found that exercise possibly improved
mood, but did not affect quality of life [26]. This lack of
Table 2 Outcomes and risk of bias for pre-clinical studies on rodent models of Parkinson’s disease
Study Behavioral outcomes Neurobiological outcomes Major sources of risk of bias
Goes et al., 2013 [21] Forced exercise following onset of
experimental PD:
Changes in the striatum from forced exercise
following onset of experimental PD:
Performance bias: sedentary control
animals were not exposed to the
swimming training program, the
warm water or handled to be dried
off following each session.
• Decreased marker of depression
(tail suspension)
• Decreased interleukin 1-beta levels
(proinflammatory cytokines)
• Improved motor coordination
(decreased falls on Rotarod test)
• Attenuated inhibition of glutathione
peroxidase activity, decreased glutathione
reductase and glutathione S-transferase
activity (all markers of oxidative stress)• Improved long-term memory,
but not short-term memory in
object recognition test • Increased dopamine, homovanillic acid,
and 3,4-dihydroxyphenylacetic acid levels
Gorton et al., 2010 [17] Forced and voluntary exercise
following onset of experimental PD:
Forced and voluntary exercise following
onset of experimental PD:
Performance bias: each animal was
only evaluated on one test.
• Improved motor learning (Rotarod) • Had no effect on levels of DA in the
striatum and serotonin in the amygdala
compared to saline controls• Reduced anxiety in elevated
plus maze (passive avoidance
task, authors linked to
cognition/memory)
• Forced and voluntary exercise increased
DA in the striatum to similar levels
following MPTP or saline administration
• Had no effect on markers of
depression, sucrose preference
and tail suspension (MPTP lesion
also had no effect)
• Forced exercise increased 5HT in the
nucleus accumbens in MPTP-treated
mice compared to saline controls
Tajiri et al., 2010 [18] Exercise following onset of experimental
PD:
Exercise following onset of experimental
PD:
Information bias: exercise was started
soon (24 hrs) after toxin administration,
so the lesion may not represent a
complete PD-like model.• Improved cylinder test, amphetamine-
induced rotational test (authors linked
to cognitive-related behavior)
• Preserved nigrostriatal dopamine neurons
(increased tyrosine hydroxylase-positive
fibers)
• Increased migration of new-born neural
stem/progenitor cells toward striatum
• Up-regulated neurotrophic factors, BDNF
and GDNF, in the striatum
Aguiar et al., 2009 [19] Forced and voluntary exercise before
onset of experimental PD:
Neurobiological outcomes not assessed Information bias: behavioral testing
was soon (24 hrs) after the reserpine
administration, so the lesion may not
represent a complete PD-like model.• Improved motor deficits following a
high dose of reserpine
• Improved short-term social memory
(tested through olfactory discrimination),
with no deficit on motor or olfactory
function from the low dose of reserpine
Pothakos et al., 2009 [20] Endurance exercise before and following
onset of experimental chronic PD:
Endurance exercise before and after onset
of experimental chronic PD:
Selection biases: there was not a group
that received exercise and probenecid.
There was also not a control group
with only a saline injection. The effects
of the control solution, probenecid, on
cognition are not known.
• Reversed balance and gait performance,
restored regular movement
• Did not raise striatal DA (n = 6)
• Did not reverse loss of tyrosine-hydroxylase
fibers in substantia nigra (pars compacta)• Had no effect on learning (cued Morris
water maze), amphetamine-stimulated
locomotion or motor coordination
Fisher et al., 2004 [16] Exercise following onset of experimental PD: Exercise following onset of experimental PD: Information bias: the learning paradigm
for behavioral results (learning to stay
on the treadmill) relied substantially on
motor capacity.
• Improved velocity and endurance on
treadmill
• Had no effect on tyrosine hydroxylase
• Sensory feedback not needed over time
for behavioral response (i.e., maintaining
a forward position on treadmill), authors
suggested indicative of learning
• Up-regulated dopamine D2 receptor mRNA
expression
• Down-regulated striatal DAT
• Reversed increased nerve terminal
glutamate in striatum (as a result of MPTP)
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Table 3 Quality of the evidence and strength of recommendations for human clinical trials1
Study Can exercise improve a marker of
cognitive function?
Quality of evidence2 Strength of recommendation3
Studies that specifically measured executive function (n = 4)
McKee et al. 2013 [29] Yes Moderate Strong
Cruise et al. 2011 [26] Yes Moderate Strong
Ridgel et al. 2011 [28] Yes Moderate Strong
Tanaka et al. 2009 [27] Yes Moderate Strong
Studies that measured unspecified aspects of cognition (n = 4)
Dos Santos Mendes et al. 2012 [25] Yes Low Weak
Pompeu et al. 2012 [24] Yes Low Weak
Müller et al. 2010 [23] Yes Low Weak
Baatile et al. 2000 [22] Yes Low Weak
1Quality of evidence and strength of recommendations based on the Grades of Recommendations, Assessment, Development, and Evaluation (GRADE) ranking
system [32,33].
2The GRADE system offers four levels of evidence: high, moderate, low and very low.
3The GRADE system offers three levels for the strength of a recommendation: strong, weak, or no recommendation.
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study did not control for the benefits of social inter-
action received by the exercise group in comparison to
the control group, who were instructed to continue
with their normal routine. Both low-intensity passive
aerobic cycling [28] as well as moderate-intensity aer-
obic and anabolic exercise [26,27] were found to im-
prove executive function in PD. The fourth study
differed from the other exercise interventions because
it assessed 20 sessions of tango classes compared to
education over 12 weeks. The subjects were assessed
for cognitive function 10–12 weeks following the inter-
vention. Subjects in the tango arm improved on the
Brooks Spatial Task, a test of spatial cognition (i.e.,
mental imagery) [29]. The authors interpreted this as
an improvement in executive function.
There was substantial variety in the intensity, mode
and duration of the exercise interventions in these four
studies. One study included an exercise intervention in-
volving low-intensity passive cycling once per week for
four weeks. Another study included moderate-to-high
intensity anabolic and aerobic exercise 60 minutes per
session twice per week for 12 weeks. The intensity and
the work load of the sessions were increased over time.
Each session involved a short low-intensity aerobic
warm-up, six resistance exercises for both upper and
lower body muscle groups, and then 25–30 minutes of
aerobic exercise on a stationary bicycle, rowing machine
or treadmill. A third study included moderate-intensity
multimodal exercise training involving aerobic exercise
with the addition of resistance, coordination and balance
training 60 minutes per session, three times per week for
24 weeks. The 24-week intervention was divided into six
phases and the load was increased after each phase. Asession included five components: warm-up, stretching
before exercise, exercise, cool-down, and stretching after
exercise. The fourth study on tango implemented a stan-
dardized structured tango program for 90-minute ses-
sions twice per week for 12 weeks.
Further details of study characteristics and results for
clinical studies are summarized in Tables 4 and 5.
Major sources of risk of bias for clinical studies
Most of the studies had a selection bias from not ad-
equately standardizing control subjects. More specifically,
the subjects’ physical fitness levels and their concomitant
medications before and during the study period were not
documented and may have impacted their ability to exer-
cise and the ability to compare their potential benefits on
cognition. Additionally, information bias resulted from
variability with the timing and intensity of the exercise
intervention between subjects. Individuals may have
received different amounts and types of exercise
which could have affected the impact of exercise on
cognition.
Of the five randomized controlled clinical trials, four
studies included control groups that received the same
social interaction as the exercise intervention group.
One study [26] included a control group receiving usual
care, which did not control for the potential benefits to
the subjects’ mood and cognition from increased social
interaction through participation in the exercise inter-
vention. Overall, both the pre-clinical and clinical stud-
ies showed a trend of selective reporting for only
significant outcomes. A risk of bias across studies in-
cludes a publication bias, as studies with insignificant or
negative findings are less likely to be published. The risk
of bias for each clinical study is summarized in Table 5.
Table 4 Study characteristics of clinical trials on human Parkinson’s disease
Authors Study title Subjects Intervention Study design
Studies that specifically measured executive function (n = 4)
McKee et al. 2013 [29] The Effects of Adapted Tango on Spatial
Cognition and Disease Severity in
Parkinson’s Disease
Total n = 33 PD • Tango or education lessons Randomized
controlled trial
• n = 15 tango • Sessions 90 minutes long, 20 sessions over
12 weeks, follow-up after 10–12 weeks
• n = 13 control
Cruise et al. 2011 [26] Exercise and Parkinson's: benefits for
cognition and quality of life
Total n = 28 PD • Moderate-to-high-intensity anabolic and
aerobic exercise or usual care
Single-blind
randomized
controlled trial• n = 15 exercise
• n = 13 control • Sessions 1 hr/day, 2x/week for 12 weeks
Ridgel et al. 2011 [28] Changes in executive function after acute
bouts of passive cycling in Parkinson's
disease





• Sessions 1/week for 4 weeks
Tanaka et al. 2009 [27] Benefits of physical exercise on executive
functions in older people with Parkinson's
disease
Total n = 20 PD • Moderate-intensity multimodal exercise
training (aerobic, resistance, coordination
and balance) or usual care
Controlled trial*
• n = 10 exercise
• n = 10 control • Sessions 1 hr/day, 3x/week for 24 weeks,
intensity increased every 4 weeks
Studies that measured unspecified aspects of cognition (n = 4)
Dos Santos Mendes
et al. 2012 [25]
Motor learning, retention and transfer after
virtual-reality-based training in Parkinson's
disease - effect of motor and cognitive
demands of games: a longitudinal,
controlled clinical study
Total n = 27 • Low-intensity Wii FitTM training, involving
motor shifts and cognitive skills
Longitudinal
pre-post trial
• n = 16 PD
• n = 11 healthy
control
• Sessions 1 hr/day, 2x/week for 7 weeks,
follow-up at 60 days
Pompeu et al. 2012
[24]
Effect of Nintendo WiiTM-based motor and
cognitive training on activities of daily
living in patients with Parkinson's disease:
A randomised clinical trial




controlled trial• n = 16 exercise
& Wii • Experimental group: Wii FitTM -based
motor/cognitive training
• n = 16 exercise
no Wii Control group: balance exercises without
feedback or cognitive stimulation
• Sessions 1 hr/day, 2x/wk for 7 weeks,
follow-up at 60 days
Müller et al. 2010 [23] Effect of exercise on reactivity and motor
behaviour in patients with Parkinson's
disease
Total n = 22 PD • Single bout of high-intensity endurance
aerobic exercise (heart rate-targeted cycling)





• Randomized order 1 day apart
Baatile et al. 2000 [22] Effect of exercise on perceived quality of
life of individuals with Parkinson's disease
Total n = 6 PD • Low-intensity aerobic exercise program




• Sessions 3x/week for 8 weeks
*Subjects were assigned into the training group based on previous participation as a control in another study and upon referral by their physician. Baseline
characteristics did not differ between the groups.
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Pre-clinical evidence
The rodent studies identified in this review have sug-
gested potential mechanisms for the benefits of exercise
on cognitive improvements in PD, particularly related to
learning and memory. The mechanisms include:
1) enhanced availability of DA in projections to the
dorsal and/or ventral striatum;
2) enhanced expression of neurotrophic factors BDNF
and GDNF, which could promote plasticity for
learning and memory; and3) decreased oxidative stress and/or neuroinflammation
in the basal ganglia.
Two of the five studies that assessed biomarkers did not
find effects from exercise following toxin administration.
However, in one case forced and voluntary exercise
similarly elevated striatal DA in both MPTP- and
saline-treated groups, although there was no diffe-
rence compared to sedentary saline-treated controls
[17]. The other study used a model of chronic PD
where the toxin was administered with probenecid
over five weeks; while exercise restored regular motor
Table 5 Outcomes and risk of bias of clinical trials on human Parkinson’s disease
Study Behavioral outcomes Major sources of risk of bias
Studies that specifically measured executive function (n = 4)
McKee et al. 2013 [29] • Tango improved disease severity (UPDRS-III)
and spatial cognition/mental imagery (Brooks Spatial
Task) more than education group, maintained
gains 10–12 weeks post-intervention
• Detection bias: study was underpowered
(n = 23 tango, n = 8 education) to evaluate
some main effects within groups, so main
effect of time was evaluated
Cruise et al. 2011 [26] • Exercise improved verbal fluency and spatial working
memory on Cambridge Neuropsychological Test
Automated Battery
• Selection bias: the control group received
usual care, no control for the effect of social
interaction with exercise
• Exercise was of “possible benefit” on semantic
fluency and mood
• Information bias: the variable intensity level
of the intervention could have affected
outcomes
• Exercise did not benefit spatial or pattern recognition,
quality of life, had no negative impact
Ridgel et al. 2011 [28] • Time to complete Trail Making Test A & B (tests executive
function) decreased after passive cycling
• Selection bias: no control
• Information bias: the same test pattern was
used pre- and post-intervention, although
practice effects were attempted to be
controlled through pre-test training with
the task
• Performance improved on Trail Making Test B following
passive cycling
Tanaka et al. 2009 [27] • Exercise improved executive function for “Categories
Completed” (i.e., capacity for abstraction) and “Preservative
Errors” (i.e., mental flexibility) on the Wisconsin Card
Sorting Task
• Selection bias: small sample size, no long-term
follow-up, not purely randomized
•Information bias: no mention of medication
administration; only one participant in the group
had a heart rate monitor, so the intensity was
targeted towards the group and not the
individual
• No interactions for confounding variables: concentrated
attention, trait or state anxiety, depression
Studies that measured unspecified aspects of cognition (n = 4)
Dos Santos Mendes et al. 2012 [25] • PD showed no deficit in learning or retention on 7/10
games, deficits related to cognitive demands of tasks
• Selection bias: the baseline physical fitness of
the subjects was not compared
• PD had worse performance than healthy individuals on
5 tests
• Performance bias: no PD controls not performing
intervention, no control for enjoyment or
motivation
• PD could transfer learning to an untrained motor task at
follow-up
Pompeu et al. 2012 [24] • Both groups improved UPDRS-II, MoCA and balance, no
additional advantage from Wii FitTM
• Information bias: the baseline physical fitness
of the subjects was not compared, so potential
for differences between groups
• Improved scores on Wii FitTM games, maintained at
follow-up
• No differences in outcomes between groups pre- to
post-intervention or in follow-up
Müller et al. 2010 [23] • Reaction time increased after rest and decreased after
exercise, movement time decreased after exercise
• Selection bias: no PD control group, no healthy
controls
• Information bias: one-day washout period
(24 hours) may not have been long enough; pilot trial
• Number of correct answers decreased after rest
• Tapping rate increased after exercise
• Detection bias: unclear how reactivity was
measured• Peg insertion interval time decreased after exercise
(complex movement sequences, visual and spatial
cognition, sorting and planning)
Baatile et al. 2000 [22] • Improved UPDRS score (only total score significant) • Selection bias: limited sample size, no control
group; pilot trial
• Improved PDQ-39 score, most improved in cognition
component • Information bias: exercise intensity not
standardized
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following the chronic toxin administration were low
and potentially more difficult to increase with exercise
due to the substantial neurodegeneration.The obvious caveat to all studies using rodents to
assess cognition is that the tasks of cognition, learn-
ing and memory require motor function to evaluate
their performance. The models used in these studies
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cepted, although none of them recapitulates the indo-
lent and progressive nature of PD [35-40]. It is
unknown how the time of onset or intensity of the
exercise paradigm initiated during or following the le-
sion/toxin may affect the severity of parkinsonism.
More promising models for the future would include
transgenic or knock-in rodents characterized by ex-
pression of mutant or overexpression of wild-type α-
synuclein. A related model is the injection of syn-
thetic α-synuclein fibrils into the rodent brain. This
model shows progressive and selective loss of DA
neurons in the substantia nigra pars compacta, as
well as cell-to-cell transmission in anatomically con-
nected regions [41]. As cortical Lewy body pathology
is a major contributing factor to dementia in PD [42],
future research with models of abnormal α-synuclein
deposition may translate better into clinical research
and practice than models that create basal ganglia
lesions.
The potential for exercise to improve cognition by re-
ducing the impact of neuroinflammation is promising.
Another study in a rodent model not dependent upon a
selective dopaminergic neurotoxin found that forced
treadmill and voluntary wheel exercise in rats can also
alleviate impairments from brain inflammation on long-
term potentiation and spatial learning [43]. The authors
injected rats with lipopolysaccharides into the cerebral
ventricles to induce brain inflammation. They found that
both treadmill and wheel training improved the resulting
deterioration in spatial learning. The effects of exercise
on learning were attributed to enhanced expression of
BDNF, tyrosine kinase B and phosphorylated cyclic AMP
response element binding protein in the hippocampus.
The impact of the injection on neuroinflammation was
not documented. This model results in preferential but
not entirely selective nigral DA cell degeneration and
the findings may thus provide insight into potential
mechanisms of exercise in humans to reduce brain in-
flammation and improve cognition.
Overall, the results from these studies on rodent models
of PD offer promising support for exercise to improve
cognition in humans with PD through the promotion of
neuronal proliferation, neuroprotection, neurogenesis, and
potentially reduction in brain inflammation. These results
support recent work that highlights how exercise likely
promotes neurorestoration through activation of signaling
cascades by neurotrophic factors [44]. Exercise has been
shown to affect regulation of DA function, including up-
regulated DA D2 receptor mRNA and down-regulated
striatal DAT in rodents [16]. High-intensity exercise also
increased DA D2 receptor availability in a recent feasibility
study by the same group using five human subjects (n = 2
PD exercise, n = 2 PD no exercise, n = 1 healthy control)and positron emission tomography with [18F]fallypride
[45]. While this small human trial does not assess cogni-
tion, these findings encourage more clinical trials based
on rodent outcomes in this field. Overall, the evidence
from rodent studies in this systematic review cannot be
directly applied to mechanisms in humans yet, but they
suggest that PD patients would likely experience a mean-
ingful improvement in cognition in response to exercise.
Clinical evidence
Clinical studies in humans demonstrate that various mo-
dalities and intensity levels of exercise can improve cog-
nitive capacity in PD, and especially executive function,
although the mechanisms have not yet been determined.
Cognitive dysfunction in PD is commonly associated
with impaired executive function [46]. However, evaluat-
ing research on cognition, and particularly executive
function, in PD is challenging because mild cognitive
impairment (MCI) in PD has only recently been defined
and formal diagnostic criteria are still in development
[47]. Selection and interpretation of measures of execu-
tive function in PD have been challenging and the clin-
ical implications are not yet fully appreciated [48].
Executive function is generally related to goal-directed
behaviors processed by the frontal lobes of the brain. Ex-
ecutive function has been categorized into four compo-
nents: planning, purposive action, effective performance
and volition [49]. It is not known what frequency, inten-
sity, type or timing of exercise might be most effective
to improve executive function in PD, but there is evi-
dence in older adults without PD that light aerobic exer-
cise (walking), and not anaerobic exercise (stretching
and toning), selectively improves executive functions
processed in the frontal and prefrontal areas of the brain
[50]. The potential different effects of aerobic compared
to anaerobic exercise on cognition in PD have not yet
been studied.
Exercise in animal models of PD may induce DA re-
lease and enhance DA transmission via up-regulation of
DA D2 receptors [51,52]. A systematic review on the ef-
fects of exercise in the elderly showed that moderate-
intensity exercise can effectively increase peripheral
BDNF [53]. Serum BDNF crosses the blood–brain bar-
rier so these results may have implications for brain neu-
rotrophin levels [54]. One of the animal studies reviewed
in this paper also found that exercise increased BDNF
and GDNF in the striatum [18]. The findings from this
review support the theory of potential neuroprotective
benefits of exercise for human PD. A recent review on
the benefit of exercise to improve cognition emphasized
the potential neuroprotective effects of vigorous exercise
in PD [13]. The authors provided guidelines including
vigorous exercise, structured programs for cognitively
impaired patients, and therapies that replenish DA to
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cise [13]. In addition to these guidelines, the current sys-
tematic review shows that any exercise should be
encouraged as it may benefit numerous aspects of pa-
tients’ cognitive function and these effects could be
transferrable to other tasks. Importantly, the effects of
vigorous exercise can last up to 60 days [25,29]. In these
studies there was overall a high retention rate for subjects
committing to a twice or three times weekly exercise pro-
gram, suggesting that these interventions could be feasibly
implemented as treatment programs. A recent meta-
analysis showed that very light to vigorous exercise seems
to have a small effect on cognition in the acute phase fol-
lowing exercise, but larger longer-lasting effects are pos-
sible with more intense exercise [55].
The benefits of exercise on cognition in PD are com-
parable to those seen in healthy older adults. A recent
review showed that endurance and resistance exercise
can improve cognition in healthy seniors [7]. There is
less research on the effects of exercise in frail older
adults, but recent evidence showed that a three-month
physical activity intervention improved physical abilities,
executive functions, processing speed and working mem-
ory [56]. The effects of exercise on cognition in older
adults with MCI are less promising, as a recent meta-
analysis showed only limited potential to improve cogni-
tion [57]. However, the interpretation is constrained
because many of the publications were deemed by the
authors of this analysis to be of moderate quality and
many of the studies were underpowered. It is possible
that exercise may have an impact on dopaminergic sig-
naling that renders it particularly valuable in PD.
Whether cognition in PD is improved due to dopa-
minergic mechanisms of exercise or other mechanisms
such as increased neurotrophic factor availability or
reduced neuroinflammation remains to be determined.
Limitations
Limitations at the level of each study include risk of in-
formation, performance and/or selection biases (Tables 2
and 5) as well as confounds inherent with the limitations
of non-randomized trials. There was overall a lack of
reporting of concomitant medications (i.e., PD therapies
and antidepressants) as well as the medical condition of
the subjects, which could have affected the results. The
limitations of this review include potential for incom-
plete retrieval of information given the search strategy
and inclusion criteria. Additionally, it is not known
whether there are genetic factors underlying response to
exercise in PD.
Conclusions
Overall, this systematic review found that exercise can im-
prove cognitive function in animal models and human PD.Pre-clinical studies showed exercise results in behavioral
and corresponding neurobiological changes in the basal
ganglia related to cognition. Specifically, learning and
memory improved after exercise in the rodents, although
the exact mechanisms remain unclear and merit further re-
search. Pre-clinical studies also showed that any exercise is
better than inactivity and that forced exercise has a greater
impact than self-paced voluntary exercise. Exercise resulted
in structural, neurochemical and molecular changes in ro-
dents, which may be of relevance to the human disorder.
The clinical studies showed that various types of exercise,
including aerobic, resistance and dance can improve cogni-
tive function, especially executive function in PD patients.
However, the best type, amount, mechanisms, and duration
of exercise are not yet known. The evidence from clinical
studies suggests that a more intensive aerobic exercise pro-
gram including strength and balance training can promote
greater cognitive gains. However, low-intensity exercise
and balance-based exercises also showed benefits.
Research on the effects of exercise on cognition in PD
is a relatively new area. As outlined in this review, there
are several limitations with the current studies in terms
of study design and risks of bias. Questions that remain
to be addressed include the prescription of exercise, if
any, which elicits the most gains as well as the duration
of effects. Future research on the effects of exercise on
cognition in PD should include a longitudinal random-
ized controlled clinical trial examining neurobiological
mechanisms in vivo, including neuroimaging. Under-
standing the mechanism of benefit from exercise could
help us to harness its potential neuroprotective effects.
Patients should use these findings as further rationale to
increase their daily physical activity. With growing sup-
port for exercise to improve not only motor symptoms,
but also cognitive impairments in PD, health care pro-
viders and policy makers should recommend exercise
as part of routine management and neurorehabilitation
for PD.
Appendix
Appendix 1: Methodology on information sources, study
search and collection
The following electronic databases were searched for ar-
ticles: PubMed, Web of Knowledge, and EBM Reviews
(OvidSP). The primary search parameter for each data-
base used the keywords, “Parkinson’s disease” AND “ex-
ercise” AND “cognition” with the Boolean operator
“AND”. Additional keywords related to cognition were
also searched by replacing “cognition” in the primary
keyword phrase one at a time with each of “dementia”,
“Alzheimer”, “memory”, “executive function”, and “im-
pulse”. Additional studies were identified by ancestry
searches of the articles yielded from the electronic
search. No limits were provided for any of the database
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search, screen and identification of eligible studies (Figure 1).
All studies identified through the information sources were
compiled on the citation manager, EndNote. The titles of
each study were then screened to identify PD participants,
including human subjects or PD-like animal models. The
abstracts of each remaining study were then searched manu-
ally for the eligibility criteria. The full text was searched for
articles deemed to meet the eligibility criteria based on their
title and abstract. All data were extracted by the study au-
thor DM in their existing form from the articles. The col-
lected data and risk of bias [32] was used to assess the
clinical studies for their quality of the evidence and deter-
mine the strength of the recommendations (Table 3) based
on the Grades of Recommendations, Assessment, Develop-
ment, and Evaluation (GRADE) ranking system [33]. The
clinical studies were assigned the same GRADE rankings by
two independent raters (DM and MS).
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Additional file 1: PRISMA Guidelines Checklist.
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